Insider Trading activities of Neurocrine Biosciences Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurocrine Biosciences Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc since year 2005. Table 2 shows the detailed insider transactions of Neurocrine Biosciences Inc since 2005. The reporting company's ticker symbol is NBIX. The reporting company's CIK number is 914475.
The total value of stock buying since 2005 is $10,350,601.
The total value of stock sales since 2005 is $101,285,623.
The total value of stock option exercises since 2005 is $11,415,605.


 1   2 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Neurocrine Biosciences Inc (NBIX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-10 0 $0 6,925 $422,702 6,925 $59,901
2017-09 0 $0 124,560 $7,341,557 124,560 $1,222,507
2017-08 0 $0 42,854 $2,244,470 65,354 $503,639
2017-07 0 $0 8,734 $436,700 8,734 $75,549
2017-05 0 $0 187,333 $10,020,224 192,333 $1,243,135
2017-04 0 $0 97,986 $4,979,646 20,000 $68,000
2017-02 0 $0 31,345 $1,337,611 119,161 $322,426
2017-01 0 $0 23,875 $1,002,086 0 $0
2016-12 0 $0 0 $0 9,100 $23,569
2016-11 0 $0 25,000 $1,321,000 0 $0
2016-09 0 $0 9,000 $450,000 9,000 $139,050
2016-08 0 $0 17,500 $851,825 0 $0
2016-05 0 $0 52,500 $2,450,800 45,000 $138,150
2016-04 0 $0 66,770 $2,953,272 56,770 $286,645
2016-02 0 $0 10,250 $389,852 20,000 $61,400
2016-01 0 $0 23,875 $1,086,325 0 $0
2015-11 0 $0 33,761 $1,832,432 33,761 $488,862
2015-10 0 $0 158,500 $7,572,295 0 $0
2015-09 0 $0 15,000 $822,450 0 $0
2015-07 0 $0 90,896 $4,799,280 90,896 $523,560
2015-06 0 $0 143,230 $6,379,973 143,230 $587,710
2015-05 0 $0 0 $0 15,000 $71,400
2015-04 0 $0 0 $0 45,000 $214,200
2015-03 0 $0 110,000 $4,686,700 80,000 $207,200
2015-02 0 $0 40,000 $1,500,000 47,500 $266,100
2015-01 0 $0 276,875 $7,802,751 260,500 $910,269
2014-12 0 $0 251,000 $5,719,032 271,000 $963,877
2014-11 0 $0 50,000 $964,076 0 $0
2014-10 0 $0 31,275 $575,962 0 $0
2014-09 0 $0 20,000 $313,200 0 $0
2014-05 0 $0 0 $0 24,000 $296,880
2014-04 0 $0 0 $0 39,000 $482,430
2014-03 0 $0 0 $0 85,000 $933,300
2014-01 0 $0 299,750 $5,257,490 50,000 $192,750
2013-09 0 $0 7,400 $117,464 0 $0
2013-08 0 $0 86,531 $1,299,574 0 $0
2013-07 0 $0 5,000 $72,500 0 $0
2013-06 0 $0 151,674 $1,921,958 0 $0
2013-03 0 $0 0 $0 63,000 $667,800
2012-12 0 $0 900 $6,669 0 $0
2011-10 103,400 $589,160 0 $0 0 $0
2011-02 0 $0 77,000 $525,602 0 $0
2010-04 0 $0 198,000 $550,660 0 $0
2010-03 0 $0 789,384 $2,128,562 0 $0
2010-01 0 $0 30,596 $77,702 0 $0
2009-11 900 $1,953 0 $0 0 $0
2009-09 0 $0 11,539 $35,930 0 $0
2009-03 0 $0 76,911 $263,660 0 $0
2009-01 123,500 $380,008 29,778 $99,593 0 $0
2008-12 110,000 $262,772 0 $0 0 $0
2008-11 54,400 $133,225 0 $0 0 $0
2008-10 447,047 $1,215,967 0 $0 0 $0
2008-09 0 $0 11,459 $53,804 0 $0
2008-07 156,800 $662,245 0 $0 0 $0
2008-05 179,700 $834,604 6,485 $32,749 0 $0
2008-03 890,700 $4,399,102 0 $0 0 $0
2008-02 384,200 $1,871,565 35,344 $178,376 0 $0
2007-04 0 $0 0 $0 63,091 $465,296
2006-05 0 $0 115,481 $2,306,963 0 $0
2006-03 0 $0 10,000 $700,130 0 $0
2005-12 0 $0 18,000 $1,148,547 0 $0
2005-11 0 $0 40,000 $2,314,219 0 $0
2005-10 0 $0 10,000 $515,000 0 $0
2005-09 0 $0 20,000 $990,000 0 $0
2005-08 0 $0 5,000 $233,750 0 $0
2005-06 0 $0 5,000 $198,500 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Neurocrine Biosciences Inc insiders (NBIX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-10-02 Obrien Christopher Flint (Chief Medical Officer) Sale 6,925 61.04 422,702
2017-10-02 Obrien Christopher Flint (Chief Medical Officer) Option Ex 6,925 8.65 59,901
2017-09-06 Gano Kyle (Chief Business Development Officer) Sale 25,000 60.00 1,500,000
2017-09-06 Gano Kyle (Chief Business Development Officer) Option Ex 25,000 8.65 216,249
2017-09-06 Lippoldt Darin (Chief Legal Officer) Sale 100 60.00 6,000
2017-09-06 Lippoldt Darin (Chief Legal Officer) Option Ex 100 18.15 1,814
2017-09-06 Bozigian Haig P. (Chief Development Officer) Sale 26,250 60.00 1,575,000
2017-09-06 Bozigian Haig P. (Chief Development Officer) Option Ex 26,250 14.12 370,650
2017-09-05 Obrien Christopher Flint (Chief Medical Officer) Sale 52,817 57.50 3,036,977
2017-09-05 Obrien Christopher Flint (Chief Medical Officer) Option Ex 52,817 8.66 457,395
2017-08-09 Lippoldt Darin (Chief Legal Officer) Sale 5,000 55.00 275,000
2017-08-09 Lippoldt Darin (Chief Legal Officer) Option Ex 5,000 18.15 90,750
2017-08-09 Grigoriadis Dimitri E. (Chief Research Officer) Sale 15,354 55.00 844,470
2017-08-09 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 15,354 5.76 88,439
2017-08-04 Bozigian Haig P. (Chief Development Officer) Sale 22,500 50.00 1,125,000
2017-08-04 Bozigian Haig P. (Chief Development Officer) Option Ex 45,000 7.21 324,450
2017-07-27 Obrien Christopher Flint (Chief Medical Officer) Sale 8,734 50.00 436,700
2017-07-27 Obrien Christopher Flint (Chief Medical Officer) Option Ex 8,734 8.65 75,549
2017-05-23 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,000 53.39 533,900
2017-05-19 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 4,980 54.00 268,920
2017-05-19 Lloyd-smith Malcolm (Chief Regulatory Officer) Option Ex 4,980 15.45 76,941
2017-05-18 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 4,980 53.26 265,234
2017-05-18 Lloyd-smith Malcolm (Chief Regulatory Officer) Option Ex 4,980 15.45 76,941
2017-05-18 Lippoldt Darin (Chief Legal Officer) Sale 10,000 53.27 532,700
2017-05-18 Lippoldt Darin (Chief Legal Officer) Option Ex 10,000 18.15 181,500
2017-05-18 Obrien Christopher Flint (Chief Medical Officer) Sale 105,634 53.32 5,632,404
2017-05-18 Obrien Christopher Flint (Chief Medical Officer) Option Ex 105,634 6.73 710,599
2017-05-05 Nevinny Corinne H (Director) Sale 5,000 53.98 269,900
2017-05-03 Nevinny Corinne H (Director) Option Ex 15,000 3.40 51,000
2017-05-03 Pops Richard F (Director) Option Ex 15,000 3.40 51,000
2017-05-02 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,000 55.00 550,000
2017-05-02 Gorman Kevin Charles (Chief Executive Officer) Sale 21,739 53.23 1,157,166
2017-05-02 Gorman Kevin Charles (Chief Executive Officer) Option Ex 21,739 2.59 56,304
2017-05-01 Gano Kyle (Chief Business Development Officer) Sale 15,000 54.00 810,000
2017-05-01 Gano Kyle (Chief Business Development Officer) Option Ex 15,000 2.59 38,850
2017-04-12 Gano Kyle (Chief Business Development Officer) Sale 13,065 50.82 663,963
2017-04-12 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 13,065 50.82 663,963
2017-04-12 Lippoldt Darin (Chief Legal Officer) Sale 13,065 50.82 663,963
2017-04-12 Grigoriadis Dimitri E. (Chief Research Officer) Sale 13,065 50.82 663,963
2017-04-12 Bozigian Haig P. (Chief Development Officer) Sale 13,065 50.82 663,963
2017-04-12 Obrien Christopher Flint (Chief Medical Officer) Sale 13,065 50.82 663,963
2017-04-12 Gorman Kevin Charles (Chief Executive Officer) Sale 19,596 50.82 995,868
2017-04-12 Mollica Joseph A (Director) Option Ex 20,000 3.40 68,000
2017-02-14 Lyons Gary A (Director) Option Ex 15,000 3.40 51,000
2017-02-08 Gorman Kevin Charles (Chief Executive Officer) Option Ex 64,161 2.59 166,176
2017-02-07 Benevich Eric (Chief Commercial Officer) Sale 132 44.65 5,893
2017-02-07 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 116 44.61 5,174
2017-02-07 Lippoldt Darin (Chief Legal Officer) Sale 132 44.62 5,889
2017-02-07 Sherwin Stephen A (Director) Option Ex 15,000 3.40 51,000
2017-02-06 Benevich Eric (Chief Commercial Officer) Sale 821 43.11 35,393
2017-02-06 Gano Kyle (Chief Business Development Officer) Sale 727 43.15 31,370
2017-02-06 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 727 43.15 31,370
2017-02-06 Lippoldt Darin (Chief Legal Officer) Sale 821 43.13 35,409
2017-02-06 Grigoriadis Dimitri E. (Chief Research Officer) Sale 727 43.13 31,355
2017-02-06 Bozigian Haig P. (Chief Development Officer) Sale 963 43.14 41,543
2017-02-06 Coughlin Timothy P (Chief Financial Officer) Sale 963 43.14 41,543
2017-02-06 Obrien Christopher Flint (Chief Medical Officer) Sale 1,206 43.17 52,063
2017-02-06 Gorman Kevin Charles (Chief Executive Officer) Sale 3,010 43.18 129,971
2017-02-03 Gano Kyle (Chief Business Development Officer) Sale 1,375 42.57 58,533
2017-02-03 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,375 42.56 58,520
2017-02-03 Bozigian Haig P. (Chief Development Officer) Sale 1,375 42.57 58,533
2017-02-03 Coughlin Timothy P (Chief Financial Officer) Sale 1,500 42.55 63,824
2017-02-03 Obrien Christopher Flint (Chief Medical Officer) Sale 1,500 42.50 63,750
2017-02-03 Gorman Kevin Charles (Chief Executive Officer) Sale 3,125 42.55 132,968
2017-02-01 Rastetter William H (Director) Sale 10,750 42.28 454,510
2017-02-01 Rastetter William H (Director) Option Ex 25,000 2.17 54,250
2017-01-17 Gano Kyle (Chief Business Development Officer) Sale 1,625 40.65 66,056
2017-01-17 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 40.63 66,023
2017-01-17 Bozigian Haig P. (Chief Development Officer) Sale 1,625 40.63 66,023
2017-01-17 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 40.65 71,137
2017-01-17 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 40.66 71,155
2017-01-17 Gorman Kevin Charles (Chief Executive Officer) Sale 3,750 40.65 152,437
2017-01-10 Gano Kyle (Chief Business Development Officer) Sale 1,250 43.37 54,212
2017-01-10 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 43.39 70,508
2017-01-10 Bozigian Haig P. (Chief Development Officer) Sale 1,625 43.37 70,476
2017-01-10 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 43.37 75,897
2017-01-10 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 43.35 75,862
2017-01-10 Gorman Kevin Charles (Chief Executive Officer) Sale 3,750 43.28 162,300
2016-12-23 Gorman Kevin Charles (President and CEO) Option Ex 9,100 2.59 23,569
2016-11-15 Obrien Christopher Flint (Chief Medical Officer) Sale 25,000 52.84 1,321,000
2016-09-01 Lloyd-smith Malcolm (Chief Regulatory Officer) Sale 9,000 50.00 450,000
2016-09-01 Lloyd-smith Malcolm (Chief Regulatory Officer) Option Ex 9,000 15.45 139,050
2016-08-15 Obrien Christopher Flint (Chief Medical Officer) Sale 12,500 48.73 609,125
2016-08-08 Nevinny Corinne H (Director) Sale 5,000 48.54 242,700
2016-05-31 Obrien Christopher Flint (Chief Medical Officer) Sale 12,500 50.00 625,000
2016-05-25 Pops Richard F (Director) Sale 15,000 46.72 700,800
2016-05-16 Obrien Christopher Flint (Chief Medical Officer) Sale 25,000 45.00 1,125,000
2016-05-16 Pops Richard F (Director) Option Ex 15,000 3.07 46,050
2016-05-06 Lyons Gary A (Director) Option Ex 15,000 3.07 46,050
2016-05-03 Nevinny Corinne H (Director) Option Ex 15,000 3.07 46,050
2016-04-14 Sherwin Stephen A (Director) Option Ex 15,000 3.07 46,050
2016-04-11 Gano Kyle (Chief Business Development Officer) Sale 41,770 43.77 1,828,272
2016-04-11 Gano Kyle (Chief Business Development Officer) Option Ex 41,770 5.76 240,595
2016-04-06 Obrien Christopher Flint (Chief Medical Officer) Sale 25,000 45.00 1,125,000
2016-02-10 Mollica Joseph A (Director) Option Ex 20,000 3.07 61,400
2016-02-03 Gano Kyle (Chief Business Development Officer) Sale 1,375 37.98 52,222
2016-02-03 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,375 37.98 52,222
2016-02-03 Bozigian Haig P. (Chief Development Officer) Sale 1,375 38.13 52,428
2016-02-03 Coughlin Timothy P (Chief Financial Officer) Sale 1,500 38.06 57,090
2016-02-03 Obrien Christopher Flint (Chief Medical Officer) Sale 1,500 38.01 57,015
2016-02-03 Gorman Kevin Charles (President and CEO) Sale 3,125 38.04 118,875
2016-01-19 Gano Kyle (Chief Business Development Officer) Sale 1,625 46.84 76,115
2016-01-19 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 46.76 75,985
2016-01-19 Bozigian Haig P. (Chief Development Officer) Sale 1,625 46.77 76,001
2016-01-19 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 46.69 81,707
2016-01-19 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 46.77 81,847
2016-01-19 Gorman Kevin Charles (President and CEO) Sale 3,750 46.70 175,125
2016-01-11 Gano Kyle (Chief Business Development Officer) Sale 1,250 44.23 55,287
2016-01-11 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 44.21 71,841
2016-01-11 Bozigian Haig P. (Chief Development Officer) Sale 1,625 44.25 71,906
2016-01-11 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 44.25 77,437
2016-01-11 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 44.25 77,437
2016-01-11 Gorman Kevin Charles (President and CEO) Sale 3,750 44.17 165,637
2015-11-27 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,000 57.50 575,000
2015-11-27 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 10,000 5.76 57,600
2015-11-09 Lippoldt Darin (Chief Legal Officer) Sale 23,761 52.92 1,257,432
2015-11-09 Lippoldt Darin (Chief Legal Officer) Option Ex 23,761 18.15 431,262
2015-10-16 Gano Kyle (Chief Business Development Officer) Sale 25,000 47.77 1,194,250
2015-10-16 Grigoriadis Dimitri E. (Chief Research Officer) Sale 25,000 47.77 1,194,250
2015-10-16 Bozigian Haig P. (Chief Development Officer) Sale 25,000 47.78 1,194,500
2015-10-16 Coughlin Timothy P (Chief Financial Officer) Sale 25,000 47.78 1,194,500
2015-10-16 Obrien Christopher Flint (Chief Medical Officer) Sale 25,000 47.78 1,194,500
2015-10-16 Gorman Kevin Charles (President and CEO) Sale 33,500 47.77 1,600,295
2015-09-18 Lyons Gary A (Director) Sale 15,000 54.83 822,450
2015-07-20 Grigoriadis Dimitri E. (Chief Research Officer) Sale 19,646 55.00 1,080,530
2015-07-20 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 19,646 5.76 113,160
2015-07-20 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 55.00 1,100,000
2015-07-20 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 5.76 115,200
2015-07-20 Obrien Christopher Flint (Chief Medical Officer) Sale 11,250 55.00 618,750
2015-07-20 Obrien Christopher Flint (Chief Medical Officer) Option Ex 11,250 5.76 64,800
2015-07-13 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,000 50.00 500,000
2015-07-13 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 10,000 5.76 57,600
2015-07-13 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 50.00 1,000,000
2015-07-13 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 5.76 115,200
2015-07-13 Obrien Christopher Flint (Chief Medical Officer) Sale 10,000 50.00 500,000
2015-07-13 Obrien Christopher Flint (Chief Medical Officer) Option Ex 10,000 5.76 57,600
2015-06-23 Mitchell W Thomas (Director) Sale 15,000 49.35 740,250
2015-06-23 Mitchell W Thomas (Director) Option Ex 15,000 6.66 99,900
2015-06-08 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,000 45.00 450,000
2015-06-08 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 10,000 5.76 57,600
2015-06-08 Coughlin Timothy P (Chief Financial Officer) Sale 60,000 45.08 2,704,800
2015-06-08 Coughlin Timothy P (Chief Financial Officer) Option Ex 60,000 2.59 155,400
2015-06-08 Obrien Christopher Flint (Chief Medical Officer) Sale 10,000 45.00 450,000
2015-06-08 Obrien Christopher Flint (Chief Medical Officer) Option Ex 10,000 5.76 57,600
2015-06-01 Gano Kyle (See Remarks) Sale 38,230 42.19 1,612,923
2015-06-01 Gano Kyle (See Remarks) Option Ex 38,230 4.17 159,610
2015-06-01 Obrien Christopher Flint (Chief Medical Officer) Sale 10,000 42.20 422,000
2015-06-01 Obrien Christopher Flint (Chief Medical Officer) Option Ex 10,000 5.76 57,600
2015-05-11 Pops Richard F (Director) Option Ex 15,000 4.76 71,400
2015-04-08 Nevinny Corinne H (Director) Option Ex 15,000 4.76 71,400
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX, CIK number 914475) see the Securities and Exchange Commission (SEC) website.